Aldeyra Therapeutics Updates Corporate Contact Info in 8-K Filing
Ticker: ALDX · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1341235
Complexity: simple
Sentiment: neutral
Topics: corporate-update, administrative, 8-K
TL;DR
**Aldeyra Therapeutics filed an 8-K updating its address and phone number, a routine administrative update.**
AI Summary
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on January 4, 2024, to update its corporate information, including its business address at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421, and its telephone number (781) 761-4904. This filing primarily serves to ensure the company's public records are current and accurate, which is important for investors to have reliable contact information and understand the company's operational base.
Why It Matters
This filing ensures Aldeyra Therapeutics' public records are accurate, providing investors with current contact and operational information, which is crucial for transparency and due diligence.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative, updating contact information, and does not indicate any operational or financial risks.
Analyst Insight
A smart investor would note this as a routine administrative update, confirming the company's public information is current, but it provides no new material information for investment decisions.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — the registrant filing the 8-K
- 131 Hartwell Avenue, Suite 320, Lexington, MA 02421 (address) — the principal executive offices of Aldeyra Therapeutics, Inc.
- (781) 761-4904 (phone_number) — the business telephone number of Aldeyra Therapeutics, Inc.
- Delaware (state) — state of incorporation for Aldeyra Therapeutics, Inc.
- 001-36332 (string) — Commission File No. for Aldeyra Therapeutics, Inc.
- ALDX (string) — trading symbol for Aldeyra Therapeutics, Inc.
- The Nasdaq Stock Market LLC (exchange) — exchange where Aldeyra Therapeutics, Inc. common stock is registered
- January 4, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the primary purpose of Aldeyra Therapeutics, Inc.'s 8-K filing on January 4, 2024?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits,' specifically updating the company's corporate information, including its business address and telephone number, as of January 4, 2024.
What is the updated business address for Aldeyra Therapeutics, Inc. as stated in the filing?
The updated business address for Aldeyra Therapeutics, Inc. is 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What is the current business telephone number for Aldeyra Therapeutics, Inc. according to this 8-K?
The current business telephone number for Aldeyra Therapeutics, Inc. is (781) 761-4904.
On which stock exchange is Aldeyra Therapeutics, Inc.'s Common Stock registered?
Aldeyra Therapeutics, Inc.'s Common Stock, with a $0.001 par value per share and trading symbol ALDX, is registered on The Nasdaq Stock Market LLC.
What was the 'Date of earliest event reported' for this 8-K filing?
The 'Date of earliest event reported' for this 8-K filing was January 4, 2024.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 9.5 · Accepted 2024-01-04 07:00:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- a53876982.htm (8-K) — 33KB
- a53876982ex99_1.htm (EX-99.1) — 19KB
- 0001157523-24-000014.txt ( ) — 194KB
- aldx-20240104.xsd (EX-101.SCH) — 4KB
- aldx-20240104_lab.xml (EX-101.LAB) — 22KB
- aldx-20240104_pre.xml (EX-101.PRE) — 16KB
- a53876982_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On January 4, 2024, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") providing a clinical and regulatory update. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated January 4, 2024